Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Mabworks Plans Hong Kong IPO to Support Antibody/Multi-Specifics Pipeline

publication date: Jul 21, 2021

Beijing Mabworks Biotech has filed an application to IPO on the  Hong Kong Exchange. The company is developing mAbs and multi-specific antibodies for oncology and autoimmune diseases. Its pipeline consists of six clinical-stage drug candidates and six preclinical candidates, plus an Avastin biosimilar that Mabworks out-licensed to Betta Pharma of Hangzhou. The company's lead candidate is MIL62, a third-gen CD20 multi-specific that is slated to begin Phase III trials in lymphoma. Because the application was the first filing, no financial details of the IPO were included. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China